Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Shows Januvia(TM) (sitagliptin) Offered Significant Blood Sugar-Lowering Efficacy In Combination With Insulin In Type 2 Diabetes
A new investigational study presented at the American Diabetes Association (ADA) 69th Annual Scientific Sessions showed that "Januvia" (sitagliptin), when added to ongoing insulin therapy with or without metformin, significantly improved blood sugar control.[i] Applications to use "Januvia" and "Janumet"* (sitagliptin/metformin) in combination with insulin have been accepted for review by the European Medicines Agency (EMEA) and by the U.S. Food and Drug Administration (FDA) and are currently under review.
generic viagra online
Consider Closing Schools To Slow Swine Flu Spread Says WHO
The World Health Organization (WHO) said earlier today, Tuesday, that countries should consider closing schools as a way to slow the spread of
News of the day
GP Bodies Support Guidelines For Use Of Patient Records In Medical Research
The two leading bodies representing GPs in the UK have backed a call by the Wellcome Trust for clearer guidance for GPs to ensure medical records can be safely used in research.
Endocrinology

Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth

Pfizer Inc (NYSE: PFE) announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company"s pending acquisition of Wyeth. The Commission"s decision includes Pfizer"s commitment to divest certain animal health assets in the EU. "We are pleased to have achieved another significant milestone for the pending acquisition with the EC"s approval of the transaction," said Amy Schulman, senior vice president and general counsel of Pfizer. In addition, Pfizer announced that China"s Ministry of Commerce has extended its review of Pfizer"s regulatory submission beyond the initial thirty-day period. The completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, governmental and regulatory approvals in certain other jurisdictions, and approval by the stockholders of Wyeth. Ms. Schulman stated, "We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close at the end of the third quarter or during the fourth quarter of 2009." Pfizer Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009